Bank of America sees positive April data for Tenet Healthcare, neutral for HCA Healthcare

Bank of America’s April foot-traffic data points to mixed-to-negative Q2 volume trends for hospital operators, with Tenet Healthcare implied at 3.5% growth versus 1.3% consensus and HCA at 2.1% in line with consensus. Universal Health Services and Acadia Healthcare look weaker, with implied growth of 0.0% vs 2.1% consensus for UHS and 1.1% vs 4.6% for ACHC. April traffic accelerated 290bps for THC and 80bps for HCA, while UHS and ACHC decelerated.

Analysis

The market is likely underpricing the dispersion signal here: the same real-time volume proxy is flashing an early-cycle winner in THC and a late-cycle disappointment in ACHC/UHS, which matters more for multiples than the absolute growth rates. When a high-frequency channel like foot traffic starts diverging from consensus by this magnitude, the first-order earnings revision is usually only part of the move; the second-order effect is confidence in management guidance, which can compress or expand EV/EBITDA by a full turn even before print season.

THC looks best positioned because accelerating volumes at a time when peers are merely steady implies operating leverage and better conversion of incremental admissions into margin. That can create a self-reinforcing setup: analysts raise estimates, the stock rerates, and the company gains flexibility on labor and payer mix. HCA looks more like a quality hold than a momentum short — the data says “stable,” not “improving,” so upside is capped unless the broader hospital utilization backdrop surprises positively.

ACHC is the most vulnerable on a 1-3 month horizon because its trend break is large enough to challenge the narrative that behavioral health demand is still outpacing capacity expansion. If this persists into the next quarterly update, the risk is multiple de-rating rather than a small EPS miss, especially if investors start assuming utilization softness is structural rather than seasonal. UHS is less clean to short outright because flat-to-soft traffic in a defensive healthcare name can be masked by cost actions, so the cleaner expression is relative underperformance versus the stronger operator.

The contrarian read is that April may be noisy: hospital traffic can be distorted by elective procedure timing, weather, and calendar effects, so the “signal” is strongest if May confirms the spread. That said, consensus already appears complacent on the losers, which leaves better asymmetry in relative-value than in outright directionals. If this data set has been 90% correlated over multiple quarters, the key trade is not chasing the whole group — it is separating the consistent compounder from the names where estimate risk is still unpriced.

Key Decisions for Investors

• Go long THC vs. short ACHC in a 1:1 notional pair for the next 4-8 weeks; the setup favors estimate revisions and multiple expansion for THC while ACHC faces downside from consensus reset if volume weakness persists.
• Add HCA only on weakness, not momentum: use it as a defensive healthcare parking spot with limited upside and lower estimate risk; prefer stock ownership over calls given the muted signal.
• Short UHS vs. THC as a cleaner relative-value expression than an outright short; target 5-8% relative underperformance over the next quarter if traffic divergence shows up in earnings commentary.
• For tactical traders, buy THC near-term upside calls into the next monthly volume print/quarterly pre-announcement window; the payoff is asymmetric if the market starts pricing a sustained beat-and-raise cycle.
• Avoid naked short ACHC unless May data confirms deceleration; if entered, size small and cover quickly on any rebound in the proxy because behavioral health names can re-rate sharply on one good data point.